is a specialty biopharmaceutical companywith a focus on developing and marketing to urologists, endocrinologists,orthopedists and select primary care physicians. Auxilium marketsTestim(R) 1%, a topical testosterone gel, for the treatment ofhypogonadism through its approximately 190-person sales and marketingteam Auxilium has five projects in clinical development. XIAFLEX(TM)(clostridial collagenase for injection), formerly referred to as AA4500,has completed phase III clinical trials for the treatment of Dupuytren’scontracture, is in phase IIb of development for the treatment ofPeyronie’s disease and is in phase II of development for treatment ofFrozen Shoulder syndrome (Adhesive Capsulitis). Auxilium’s transmucosalfilm product candidate for the treatment of overactive bladder (AA4010)is in phase I of development. Auxilium also has one pain product(fentanyl) using its transmucosal film delivery system in phase I ofdevelopment. Auxilium has rights to additional pain products and productsfor hormone replacement and urologic disease using its transmucosal filmdelivery system.
The Company is currently seeking a partner to furtherdevelop these transmucosal film product candidates. Given these risks and uncertainties, any or all of theseforward-looking statements may prove to be incorrect. Therefore, youshould not rely on any such factors or forward-looking statements.In addition, forward-looking statements provide the Company’sexpectations, plans or forecasts of future events and views as of thedate of this release. The Company anticipates that subsequent events anddevelopments will cause the Company’s assessments to change. However,while the Company may elect to update these forward-looking statements atsome point in the future, the Company specifically disclaims anyobligation to do so.
These forward-looking statements should not berelied upon as representing the Company’s assessments as of any datesubsequent to the date of this release.For More Information, Contact:James E. FickenscherCFOAuxilium Pharmaceuticals, Inc.(484) 321-5900Email ContactWilliam Q. Sargent, Jr.V.P., IRAuxilium Pharmaceuticals, Inc.(484) 321-5900Email ContactCopyright 2009, Market Wire, All rights reserved.-0-. SUGAR LAND, TX, Apr 30 (MARKET WIRE) — Researched by Industrial Info Resources (Sugar Land, Texas) — One of thegrowing energy trends over the past few years has been the development ofcoal gasification projects. There are about 30 coal gasification projectsin the works across the United States. These are non-integratedgasification combined-cycle stand-alone projects, which aim to producevarious hydrocarbons, including liquids, liquefied natural gas, naturalgas, syngas or diesel.